BioNTech: Advancing science to help transform cancer and infectious ...
BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases.
BioNTech - Wikipedia
BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that …
BioNTech and Co-Founders Announce Plan to Pursue Next …
Mar 10, 2026 · BioNTech co-founders and mRNA technology pioneers Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D., will establish their third biotechnology company following the foundation of …
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after ...
9 hours ago · Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been …
BioNTech founders step down to start new venture - dw.com
Mar 10, 2026 · The husband-and-wife founders of German vaccine company BioNTech announced on Tuesday they would step down to pursue new innovations at a brand new firm.
BMO Capital Cuts PT on BioNTech SE (BNTX) to $128 From $143 – …
1 day ago · BioNTech SE (NASDAQ:BNTX) is one of the best high growth healthcare stocks to buy now. On March 11, BMO Capital cut the price target on BioNTech SE (NASDAQ:BNTX) to $128 from …
Why Did BioNTech Stock Surge 10% Pre-Market Today?
Mar 5, 2026 · BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate …
BioNTech and Co-Founders Announce Plan to Pursue Next ... - Nasdaq
Mar 10, 2026 · BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin …
Covid vaccine maker BioNTech offers cheap biotech play given huge
Covid vaccine maker BioNTech looks like a cheap biotechnology play after its shares got hammered last week on news that its co-founders plan to leave the cash-rich German company by the end of 2026.
BioNTech | About
BioNTech is a global biopharmaceutical company pioneering novel investigative therapies for cancer and infectious diseases. We are committed to transforming how cancer is treated.